RxDoctor Payments Data

Jared Hu

Family · Chesterfield, MONPI 1770023608

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,500 of the $30,251 with a category attached, or 77.7%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 83.0% of it on its own, with 26 other manufacturers making up the rest. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,251in general payments, 2019–2025

Across 367 payments — averaging $82.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$25K
  • Novartis$1K
  • Merck$591
  • Medtronic$464
  • Smith+Nephew$438
  • AstraZeneca$434
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$23,50078%
  • Food & beverage$6,72322%
  • Education$280%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,251 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$38,880
Medicare patients
332
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan36$55,615
EliquisApixaban27$36,889
FarxigaDapagliflozin Propanediol24$32,983
BrilintaTicagrelor32$25,309
JardianceEmpagliflozin17$23,401
Midodrine Hcl12$1,110
Losartan Potassium80$889
ClopidogrelClopidogrel Bisulfate58$816
Hydralazine Hcl71$704
Atorvastatin Calcium59$651
Amlodipine Besylate58$574
Nifedipine ErNifedipine14$530
Metoprolol Tartrate55$523
Metoprolol Succinate42$440
Spironolactone49$417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$434$58,29256 claims
NovartisEntresto$1,154$55,61536 claims
PfizerEliquis$401$36,88927 claims
Boehringer IngelheimJardiance$107$23,40117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →